益佰制药 (600594.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−26.3x

Market Cap

CNY 3.21B

MomentumView details →

1D Return

+9.95%

YTD Return

−6.28%

RSI (14)

46.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−26.3x

Market Cap

CNY 3.21B

RSI (14)

46.4

MomentumView details →

1D Return

+9.95%

YTD Return

−6.28%

ProfitabilityView details →

Gross Margin

59.15%

Net Margin

−20.33%

EBITDA Margin

−6.87%

ROE (TTM)

−16.20%

ROA (TTM)

−10.29%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

−18.19%

EPS YoY

−36.36%

FCF YoY

+414.44%

Revenue CAGR 3Y

−12.02%

EPS CAGR 3Y

−4.48%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.27x

Current Ratio

1.70x

Quick Ratio

1.06x

Div Yield

—

Div Rate

—

Div Growth 1Y

−49.23%

Financials snapshotView financials →

Revenue (TTM)

1.72B

Net Income (TTM)

−349.70M

Op. CF (TTM)

294.36M

Latest newsMore news →

Yibai Pharmaceutical announced its first-half 2026 results: revenue of 689 million yuan, down 30.58% year-on-year, and net loss attributable to shareholders widened to 80.34 million yuan from 19.90 million yuan a year earlier.15d ago

Yibai Pharmaceutical received a Notice of Administrative Penalty from the Guizhou Provincial Drug Administration for failing to comply with Good Manufacturing Practice for drugs, and is proposed to be fined 700,000 yuan.35d ago

Similar companies

Regencell Bioscience Holdings LimitedRGC 威尔药业603351.SH 康惠股份603139.SH CF PharmTech, Inc.02652.HK ST交昂600530.SH 司太立603520.SH Find similar companies →

Latest newsMore news →

Yibai Pharmaceutical announced its first-half 2026 results: revenue of 689 million yuan, down 30.58% year-on-year, and net loss attributable to shareholders widened to 80.34 million yuan from 19.90 million yuan a year earlier.15d ago Yibai Pharmaceutical received a Notice of Administrative Penalty from the Guizhou Provincial Drug Administration for failing to comply with Good Manufacturing Practice for drugs, and is proposed to be fined 700,000 yuan.35d ago